AlphaCentric Life Sciences& Hlthcare Fd earns a Low Process Pillar rating. The main detractor from the rating is high costs across its parent firm's funds, whose fees rank in their category's most ...

A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024. We're bumping up our reporting criteria from last year's ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Introduction Filgotinib (FIL), a once-daily, oral, Janus kinase 1 preferential inhibitor, is approved for the treatment of moderately to severely active rheumatoid arthritis (RA) and ulcerative ...

Reference [1]Kavanaugh A, et al. J Rheumatol 2021;48:1230–8. Acknowledgements Funding: DARWIN 3 was co-funded by Gilead Sciences Inc. (Foster City, CA, USA) and Galapagos NV (Mechelen, Belgium).

The FINCH studies were co-funded by Gilead Sciences Inc. (Foster City, CA, USA) and Galapagos NV (Mechelen, Belgium). Publication coordination was provided by Fabien Debailleul, PhD, of Galapagos NV.

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday? Why ...